Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JOSE E RODRIGUEZ

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1548506553
CMS profile
1772171
Location
FORT MYERS, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$178.48

3 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $178.48 3

By paying entity

PY2025 · entire year · sorted by reported total

Paying entityAmountRecords
Penumbra, Inc. $118.99 1
Boehringer Ingelheim Pharmaceuticals, Inc. $34.98 1
Alkermes, Inc. $24.51 1

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JOSE E RODRIGUEZ

NPI 1548506553 · CMS profile ID 1772171

Allopathic & Osteopathic Physicians / Internal Medicine

FORT MYERS, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1548506553?year=2025&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JOSE E RODRIGUEZ, NPI 1548506553, CMS profile ID 1772171. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1548506553?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). JOSE E RODRIGUEZ, NPI 1548506553, CMS profile ID 1772171. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1548506553?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
JOSE E RODRIGUEZ, NPI 1548506553, CMS profile ID 1772171, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1548506553?year=2025&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

3 matching records · $178.48 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 3 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–3 of 3.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Penumbra, Inc. $118.9911/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1185439307 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $34.9810/31/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1222858123 CMS
Alkermes, Inc. $24.5106/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1222625758 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $59.14 4
PY2020 $42.54 3
PY2022 $228.73 2
PY2025 $178.48 3

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2022, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2022 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,179,337.91 86
PY2024 Principal investigator $116,250.00 1
PY2023 Principal investigator $48,018.00 5
PY2022 Principal investigator $20,701.00 6

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

86 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ROCHE MOLECULAR SYSTEMS, INC. $1,950.00 12/31/2025 Non-covered Recipient Entity
GOLDEN RESEARCH
RD006866 No dispute reported 06/30/2026 1244347274
Principal investigator 1 Currax Pharmaceuticals LLC $2,778.32 12/24/2025 Non-covered Recipient Entity
Southwest General Healthcare Center
NB (Contrave) Cardiovascular Outcomes Trial No dispute reported 06/30/2026 1242717109
Principal investigator 1 ROCHE MOLECULAR SYSTEMS, INC. $406.00 12/01/2025 Non-covered Recipient Entity
GOLDEN RESEARCH
RD006866 No dispute reported 06/30/2026 1244347625
Principal investigator 1 ROCHE MOLECULAR SYSTEMS, INC. $58,350.00 11/21/2025 Non-covered Recipient Entity
GOLDEN RESEARCH
RD006866 No dispute reported 06/30/2026 1244347615
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,999.70 11/20/2025 Non-covered Recipient Entity
SOUTHWEST GENERAL HEALTHCARE CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184263371
Principal investigator 1 Currax Pharmaceuticals LLC $475.54 11/13/2025 Non-covered Recipient Entity
Southwest General Healthcare Center
NB (Contrave) Cardiovascular Outcomes Trial No dispute reported 06/30/2026 1242717107
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $27,327.64 11/13/2025 Non-covered Recipient Entity
SOUTHWEST GENERAL HEALTHCARE CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184260695
Principal investigator 1 ROCHE MOLECULAR SYSTEMS, INC. $406.00 11/01/2025 Non-covered Recipient Entity
GOLDEN RESEARCH
RD006866 No dispute reported 06/30/2026 1244347757
Principal investigator 1 ROCHE MOLECULAR SYSTEMS, INC. $820.05 10/17/2025 Non-covered Recipient Entity
GOLDEN RESEARCH
RD006866 No dispute reported 06/30/2026 1244347270
Principal investigator 1 ROCHE MOLECULAR SYSTEMS, INC. $820.05 10/17/2025 Non-covered Recipient Entity
GOLDEN RESEARCH
RD006866 No dispute reported 06/30/2026 1244347883
Principal investigator 1 ROCHE MOLECULAR SYSTEMS, INC. $500.00 10/16/2025 Non-covered Recipient Entity
GOLDEN RESEARCH
RD006866 No dispute reported 06/30/2026 1244347250
Principal investigator 1 ROCHE MOLECULAR SYSTEMS, INC. $68,150.00 10/16/2025 Non-covered Recipient Entity
GOLDEN RESEARCH
RD006866 No dispute reported 06/30/2026 1244347358
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $13,411.04 10/16/2025 Non-covered Recipient Entity
SOUTHWEST GENERAL HEALTHCARE CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184250621
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $10,073.42 10/16/2025 Non-covered Recipient Entity
SOUTHWEST GENERAL HEALTHCARE CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184250913
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,992.00 10/16/2025 Non-covered Recipient Entity
SOUTHWEST GENERAL HEALTHCARE CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184250915
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $29,248.09 10/16/2025 Non-covered Recipient Entity
SOUTHWEST GENERAL HEALTHCARE CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184250917
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,192.00 10/16/2025 Non-covered Recipient Entity
SOUTHWEST GENERAL HEALTHCARE CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184250919
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,196.58 10/16/2025 Non-covered Recipient Entity
SOUTHWEST GENERAL HEALTHCARE CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184250921
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,626.00 10/16/2025 Non-covered Recipient Entity
SOUTHWEST GENERAL HEALTHCARE CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184250923
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $10,572.00 10/16/2025 Non-covered Recipient Entity
SOUTHWEST GENERAL HEALTHCARE CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184250925
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $8,303.94 10/16/2025 Non-covered Recipient Entity
SOUTHWEST GENERAL HEALTHCARE CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184250927
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $18,973.78 10/16/2025 Non-covered Recipient Entity
SOUTHWEST GENERAL HEALTHCARE CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184250929
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,317.18 10/16/2025 Non-covered Recipient Entity
SOUTHWEST GENERAL HEALTHCARE CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184250931
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $10,334.10 10/16/2025 Non-covered Recipient Entity
SOUTHWEST GENERAL HEALTHCARE CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184250933
Principal investigator 1 Currax Pharmaceuticals LLC $1,426.62 10/14/2025 Non-covered Recipient Entity
Southwest General Healthcare Center
NB (Contrave) Cardiovascular Outcomes Trial No dispute reported 06/30/2026 1242717105
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $24,554.44 10/09/2025 Non-covered Recipient Entity
SOUTHWEST GENERAL HEALTHCARE CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184249160
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $27,228.10 10/03/2025 Non-covered Recipient Entity
SOUTHWEST GENERAL HEALTHCARE CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184244895
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,682.61 10/03/2025 Non-covered Recipient Entity
SOUTHWEST GENERAL HEALTHCARE CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184244897
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,683.78 10/03/2025 Non-covered Recipient Entity
SOUTHWEST GENERAL HEALTHCARE CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184244899
Principal investigator 1 ROCHE MOLECULAR SYSTEMS, INC. $406.00 10/01/2025 Non-covered Recipient Entity
GOLDEN RESEARCH
RD006866 No dispute reported 06/30/2026 1244347448
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,460.00 09/23/2025 Non-covered Recipient Entity
SOUTHWEST GENERAL HEALTHCARE CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184241818
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $41,336.40 09/23/2025 Non-covered Recipient Entity
SOUTHWEST GENERAL HEALTHCARE CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184241820
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $12,951.54 09/23/2025 Non-covered Recipient Entity
SOUTHWEST GENERAL HEALTHCARE CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184241822
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $47,853.05 09/23/2025 Non-covered Recipient Entity
SOUTHWEST GENERAL HEALTHCARE CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184241824
Principal investigator 1 ROCHE MOLECULAR SYSTEMS, INC. $2,100.00 09/20/2025 Non-covered Recipient Entity
GOLDEN RESEARCH
RD006866 No dispute reported 06/30/2026 1244347372
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,085.00 09/18/2025 Non-covered Recipient Entity
SOUTHWEST GENERAL HEALTHCARE CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184240812
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,872.00 09/18/2025 Non-covered Recipient Entity
SOUTHWEST GENERAL HEALTHCARE CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184240814
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $8,634.36 09/18/2025 Non-covered Recipient Entity
SOUTHWEST GENERAL HEALTHCARE CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184240816
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,167.05 09/18/2025 Non-covered Recipient Entity
SOUTHWEST GENERAL HEALTHCARE CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184240818
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,600.00 09/18/2025 Non-covered Recipient Entity
SOUTHWEST GENERAL HEALTHCARE CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184240820
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $198,137.30 09/10/2025 Non-covered Recipient Entity
SOUTHWEST GENERAL HEALTHCARE CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184235897
Principal investigator 1 ROCHE MOLECULAR SYSTEMS, INC. $500.00 09/09/2025 Non-covered Recipient Entity
GOLDEN RESEARCH
RD006866 No dispute reported 06/30/2026 1244347723
Principal investigator 1 ROCHE MOLECULAR SYSTEMS, INC. $102,550.00 09/08/2025 Non-covered Recipient Entity
GOLDEN RESEARCH
RD006866 No dispute reported 06/30/2026 1244347565
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,631.02 09/03/2025 Non-covered Recipient Entity
SOUTHWEST GENERAL HEALTHCARE CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184235037
Principal investigator 1 ROCHE MOLECULAR SYSTEMS, INC. $203.00 09/01/2025 Non-covered Recipient Entity
GOLDEN RESEARCH
RD006866 No dispute reported 06/30/2026 1244347466
Principal investigator 1 ROCHE MOLECULAR SYSTEMS, INC. $993.30 08/28/2025 Non-covered Recipient Entity
GOLDEN RESEARCH
RD006866 No dispute reported 06/30/2026 1244347715
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,005.36 08/21/2025 Non-covered Recipient Entity
SOUTHWEST GENERAL HEALTHCARE CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184229845
Principal investigator 1 ROCHE MOLECULAR SYSTEMS, INC. $3,250.00 08/19/2025 Non-covered Recipient Entity
GOLDEN RESEARCH
RD006866 No dispute reported 06/30/2026 1244347330
Principal investigator 1 ROCHE MOLECULAR SYSTEMS, INC. $1,080.45 08/14/2025 Non-covered Recipient Entity
GOLDEN RESEARCH
RD006866 No dispute reported 06/30/2026 1244347717
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,335.12 08/14/2025 Non-covered Recipient Entity
SOUTHWEST GENERAL HEALTHCARE CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184228531
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,340.48 08/07/2025 Non-covered Recipient Entity
SOUTHWEST GENERAL HEALTHCARE CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184226423
Principal investigator 1 ROCHE MOLECULAR SYSTEMS, INC. $203.00 08/01/2025 Non-covered Recipient Entity
GOLDEN RESEARCH
RD006866 No dispute reported 06/30/2026 1244347771
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,335.12 07/31/2025 Non-covered Recipient Entity
SOUTHWEST GENERAL HEALTHCARE CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184223028
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $460.68 07/22/2025 Non-covered Recipient Entity
SOUTHWEST GENERAL HEALTHCARE CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184217977
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,685.44 07/17/2025 Non-covered Recipient Entity
SOUTHWEST GENERAL HEALTHCARE CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184217350
Principal investigator 1 Currax Pharmaceuticals LLC $4,428.70 06/24/2025 Non-covered Recipient Entity
Southwest General Healthcare Center
NB (Contrave) Cardiovascular Outcomes Trial No dispute reported 06/30/2026 1242717103
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,229.34 06/19/2025 Non-covered Recipient Entity
SOUTHWEST GENERAL HEALTHCARE CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184209344
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,802.69 06/12/2025 Non-covered Recipient Entity
SOUTHWEST GENERAL HEALTHCARE CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184206629
Principal investigator 1 Currax Pharmaceuticals LLC $4,951.14 05/28/2025 Non-covered Recipient Entity
Southwest General Healthcare Center
NB (Contrave) Cardiovascular Outcomes Trial No dispute reported 06/30/2026 1242717101
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,894.72 05/15/2025 Non-covered Recipient Entity
SOUTHWEST GENERAL HEALTHCARE CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184194971
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,789.44 05/08/2025 Non-covered Recipient Entity
SOUTHWEST GENERAL HEALTHCARE CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184193865
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $30,144.22 04/28/2025 Non-covered Recipient Entity
SOUTHWEST GENERAL HEALTHCARE CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184190797
Principal investigator 1 Currax Pharmaceuticals LLC $6,662.28 04/24/2025 Non-covered Recipient Entity
Southwest General Healthcare Center
NB (Contrave) Cardiovascular Outcomes Trial No dispute reported 06/30/2026 1242717099
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,950.60 04/23/2025 Non-covered Recipient Entity
SOUTHWEST GENERAL HEALTHCARE CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184189141
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,901.20 04/15/2025 Non-covered Recipient Entity
SOUTHWEST GENERAL HEALTHCARE CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184183446
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $8,006.19 04/08/2025 Non-covered Recipient Entity
SOUTHWEST GENERAL HEALTHCARE CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184181998
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,425.90 04/01/2025 Non-covered Recipient Entity
SOUTHWEST GENERAL HEALTHCARE CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184180720
Principal investigator 1 Currax Pharmaceuticals LLC $21,394.18 03/27/2025 Non-covered Recipient Entity
Southwest General Healthcare Center
NB (Contrave) Cardiovascular Outcomes Trial No dispute reported 06/30/2026 1242717097
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $11,737.98 03/25/2025 Non-covered Recipient Entity
SOUTHWEST GENERAL HEALTHCARE CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184178760
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $9,140.10 03/19/2025 Non-covered Recipient Entity
SOUTHWEST GENERAL HEALTHCARE CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184174332
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $299.63 03/19/2025 Non-covered Recipient Entity
SOUTHWEST GENERAL HEALTHCARE CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184174334
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $14,360.01 03/19/2025 Non-covered Recipient Entity
SOUTHWEST GENERAL HEALTHCARE CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184174336
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,393.88 03/19/2025 Non-covered Recipient Entity
SOUTHWEST GENERAL HEALTHCARE CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184174338
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $15,323.88 03/19/2025 Non-covered Recipient Entity
SOUTHWEST GENERAL HEALTHCARE CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184174340
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $58,851.17 03/19/2025 Non-covered Recipient Entity
SOUTHWEST GENERAL HEALTHCARE CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184174342
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,772.00 03/19/2025 Non-covered Recipient Entity
SOUTHWEST GENERAL HEALTHCARE CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184174344
Principal investigator 1 Currax Pharmaceuticals LLC $8,265.00 03/06/2025 Non-covered Recipient Entity
Southwest General Healthcare Center
NB (Contrave) Cardiovascular Outcomes Trial No dispute reported 06/30/2026 1242717095
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $12,941.94 02/25/2025 Non-covered Recipient Entity
SOUTHWEST GENERAL HEALTHCARE CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184155550
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,855.00 02/25/2025 Non-covered Recipient Entity
SOUTHWEST GENERAL HEALTHCARE CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184155552
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,422.00 02/25/2025 Non-covered Recipient Entity
SOUTHWEST GENERAL HEALTHCARE CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184155554
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,470.97 02/18/2025 Non-covered Recipient Entity
SOUTHWEST GENERAL HEALTHCARE CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184154496
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $9,987.95 02/13/2025 Non-covered Recipient Entity
SOUTHWEST GENERAL HEALTHCARE CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184153946
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,995.18 02/13/2025 Non-covered Recipient Entity
SOUTHWEST GENERAL HEALTHCARE CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184153948
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $21,962.19 01/29/2025 Non-covered Recipient Entity
SOUTHWEST GENERAL HEALTHCARE CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184150020
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,995.18 01/17/2025 Non-covered Recipient Entity
SOUTHWEST GENERAL HEALTHCARE CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184148285
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $75,008.60 01/09/2025 Non-covered Recipient Entity
SOUTHWEST GENERAL HEALTHCARE CENTER
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184147371